San Diego-based mostly Viking Therapeutics marked itself as a serious competitor inside the weight loss drug marketplace in February soon after revealing promising data from a mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection and in March the